Study of GS-0151 in Participants With Rheumatoid Arthritis

Recruiting now · Phase 1 · Has a placebo group

Conditions studied: Rheumatoid Arthritis

In brief

The goal of this clinical study is to learn more about the study drug GS-0151. The study is done to find how safe, well-tolerated the drug is. This will also assess how the drug is absorbed, modified, distributed and cleared from the body (the pharmacokinetics (PK) of the drug), when given multiple times to participants with rheumatoid arthritis (RA). The primary objectives of this study is to assess the safety and tolerability of multiple ascending doses of GS-0151 in participants with RA and to characterize the PK of GS-0151 following multiple doses of GS-0151 in participants with RA.

Key facts

Study ID
NCT06902519
Run by
Gilead Sciences
People needed
75
Starts
2025-05-14
Expected to finish
2027-03-01
Last updated by the study team
2026-06-09

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.